

Investor Newsletter

Issue **12** 2014



MicroPort Attends AICT


From November 26 to November 29, the 10th Asian Interventional Cardiovascular Therapeutics (“AICT”) Congress was held in Jakarta of Indonesia. Shanghai MicroPort Medical (Group) Co (“MicroPort”) participated in the academic event along with other 31 exhibitors from Indonesia, Thailand, India, Singapore and Malaysia.



MicroPort Holds Mini Lecture

On November 29, MicroPort held a Mini Lecture in Guangzhou, Guangdong Province. The lecture was focused on complex lesions of percutaneous coronary intervention (“PCI”). Several healthcare professionals were invited to share their experience in PCI treatment with people in attendance.

MicroPort Endovascular Promotes Aegis™



From November 27 to November 30, China Endovascular Course was held in Beijing. MicroPort Endovascular (Shanghai) Co (“MicroPort Endovascular”) attended the forum with a booth that contains a special area for surgical simulation for attendees to get hands-on experience on our endovascular devices. On November 29, MicroPort hosted a workshop on Aegis™ Bifurcated Stent-graft System. Experts in attendance acknowledged the efficacy of Aegis™ and offered suggestions for further improvements as well.

MicroPort NeuroTech Attends Academic Meeting

From December 6 to December 7, the fifth Academic Annual Meeting of Stroke Prevention and Control Society & Chinese Prevention Medicine Association (“SPCS&CPMA”) was held in Hangzhou, Zhejiang Province. MicroPort NeuroTech (Shanghai) Co (“MicroPort NeuroTech”) attended the meeting and promoted our APOLLO Intracranial Stent to participants.

MicroPort Participates CBS 2014

From December 4 to December 7, the 7th Left Main & Coronary Bifurcation Summit (“CBS 2014”) was held in Nanjing, Jiangsu Province. During the meeting, MicroPort introduced the main features and advantages of Firehawk® Rapamycin Target Eluting Coronary Stent to healthcare professionals from Hong Kong, Malaysia and Indonesia. After watching two surgery videos in which Firehawk® is used to treat left main bifurcation, they spoke highly of the device and said they looked forward to seeing it launched in more markets.



Firehawk®
Rapamycin
Target Eluting
Coronary Stent
System

Castor Selected as Key Project of National Program



Castor Thoracic Branch Stent-Graft System ("Castor"), an endovascular device developed by MicroPort Endovascular, was successfully selected as one project of the National Key Technology R&D Program for China's 12th Five-Year Plan in November.

Compared with other branch stent-grafts under development, Castor has less endoleak and better branch artery patency. It also features kink-free outer sheath, arch-passing ability, soft membrane as well as soft cap with branch stent cramped in.

During the past decade, an increasingly more people suffer from thoracic dissection in China. Dissection involving left subclavian artery ("LSA") is currently a relative contraindication for endovascular treatment. In that case, the development of Castor is a crucial milestone in treatment of challenging aortic arch disease.

MicroPort has carried out clinical trials for Castor, which is the world's first large-scaled and multi-centered clinical study for branched thoracic stent graft. Its clinical efficacy has gained recognitions from domestic medical professionals.

First Clinical Implantation of Ultra Low Profile Completed

Ultra Low Profile AAA Stent-Graft System ("Ultra Low Profile"), an endovascular device in-house developed by MicroPort Endovascular, recently completed its first clinical implantation in Shanghai-based Zhongshan Hospital.

MicroPort's Ultra Low Profile is designed to treat abdominal aortic aneurysm ("AAA"), the most common form of aortic aneurysm which occurs most commonly in individuals between 65 and 75 years old, especially men and smokers. As the new generation of our AAA stent graft, Ultra Low Profile is the first and only of its kind with an outer sheath of delivery system as low as 14F in China.

The first implantation of Ultra Low Profile, done by Dr. Weiguo Fu, Head of Vascular Surgery of Zhongshan Hospital, and his team, achieved successful result, as no endoleak occurred and the aortic aneurysm was completely excluded. MicroPort will continue to carry out clinical trials for the device in around 15 medical centers in China.

"The success of the first implantation symbolizes the official kickoff of the pre-market clinical studies for Ultra Low Profile to ensure its safety and efficacy," said Zhenghua Miao, President of MicroPort Endovascular. "We hope more patients can benefit from the device in the near future."



MicroPort EP Attends Atrial Fibrillation Forum

From December 12 to December 13, Atrial Fibrillation International Forum 2014 was held in Shanghai. Shanghai MicroPort EP MedTech Co (“MicroPort EP”) attended the event and learnt up-to-date developments in atrial fibrillation treatment from domestic and international professionals.



MicroPort Endovascular Attends CIM

From December 12 to December 14, China Intervention Medicine (“CIM”) was held in Zhengzhou, Henan Province. MicroPort Endovascular participated and issued a report focused on Hercules Low-Profile and clinical data of Castor Thoracic Branch Stent-Graft System. The report attracted a lot of attention and successfully promoted our endovascular devices to participants.

Mini Lecture in Nanning

On December 21, in partnership with the First Affiliated Hospital of Guangxi Medical University, MicroPort hosted its Mini Lecture in Nanning of Guangxi Province. We invited seven healthcare professionals to share their experience in endovascular treatment of aortic diseases. We also took this opportunity to introduce our Hercules Low-Profile and Castor Thoracic Branch Stent-Graft System to people in attendance.



Occluder Delivery System Awarded Certificate

On December 19, Dongguan Kewei Medical Co (“Dongguan Kewei”) gained a registration certificate for its occluder delivery system from China Food and Drug Administration. This is our first occluder delivery system that received registration certificate, which is expected to promote the sales of our Amender™ ASD Occluder and Amender™ ASD Occluder as well.

MPSC New CHRO on Board

MicroPort Scientific Corporation ("MPSC") is pleased to announce that effective immediately Mr. Jun-der Chiang has joined MPSC as the Chief Human Resources Officer ("CHRO").



Mr. Chiang has gained rich international experience as Human Resource Senior Executive in top multinational corporations. Before joining MPSC, Mr. Chiang served as Chief People Officer for McDonald Corporation (China Operations) and worked as Senior HR Leader for General Motors (JV Liaison China) between 2005 and 2008. Mr. Chiang has also gained valuable experience working for Delphi in Singapore and USA between 1995 and 2004.

Mr. Chiang achieved his Master's degree in Business Administration in Human Resources and Organization Development from University of Illinois Urbana-Champaign in the USA. He earned a Bachelor's degree from Taiwan-based Tamkang University, majoring in Business Economics.

MicroPort Establishes Translational Medicine Joint Research Center with Second Military Medical University

MicroPort and the Second Military Medical University announced on December 19 that they have entered into an agreement to establish a Translational Medicine Joint Research Center.



Shen Gu, Head of Translational Medicine Research Center of the Second Military Medical University and Qiyi Luo, Chief Technology Officer of MicroPort signed the cooperation framework agreement on behalf of the two parties, respectively. Dr. Yinghao Sun, President of the Second Military Medical University, Dr. Zhaohua Chang, Chairman and Chief Executive Officer of MicroPort, and several executives and professors from the two sides attended the signing ceremony.

Under the agreement, the two parties will collaborate, through the Translational Medicine Joint Research Center, on several fields including internal medicine, surgery, interventional medicine, oncology, medical imaging, neurology and angiopathy.

This new Translational Medicine Joint Research Center brings together two respected parties, leveraging complementary strengths – MicroPort's rich experience in medical device industry and the Second Military Medical University's research expertise in clinical medicine – in the developments of innovative medical devices and minimally invasive surgery technologies.

"As a national key medical university, the Second Military Medical University has rich experience in clinical studies and abundant development resources. And MicroPort has placed priority on research and innovation since establishment. We believe our partnership will produce fruitful results and will promote the development of the medical device industry in China," said Dr. Chang.

"This agreement provides a significant opportunity for the Second Military Medical University, enabling us to transform the theoretical studies into clinical practices," said Dr. Sun. "We recognize MicroPort as an experienced player in the medical device industry and we are looking forward to working with it to develop the Translational Medicine Joint Research Center."

The Second Military Medical University offers 13 majors and has three nationwide famous affiliated hospitals – Shanghai Changzheng Hospital, Eastern Hepatobiliary Surgery Hospital and Changhai Hospital.



Medical Education in Phoenix Skills Lab

In December, MicroPort Orthopedics held a successful training event for SuperPath™ and EVOLUTION® Knee. At the Arizona Surgical Training Institute ("ASTI"), the teams, led by Drs. Chow and Zechmann, reviewed the benefits of the SuperPath™ Hip Technique.

Dr. Chow, who recently completed his 1,000th SuperPath™ procedure, had a great deal of data that showed the benefit of the technique to the patient. After a small didactic presentation, it was in the lab for the attendees where they gathered and performed training evaluations on cadavers.



Medial Pivot Knee tour in Latin America

The week of November 10 was special for MicroPort Orthopedics in Latin America. A "tour" of medical education activities was held in the region with the goal of promoting the Medial Pivot Knee philosophy.

Our educational offering was based on two platforms: Reversed surgical observations combined with small didactic events and didactic event with case discussions, sawbones workshop and live surgery.

We are confident that these Medical Education initiatives will contribute to the development of our Knee business in Latin America.

MicroPort Orthopedics Italy Holds Knee Didactic Training



In November, MicroPort Orthopedics Italy held the third chapter of the Advanced Knee Didactic Training combined with a live surgery observation. The aim of the meeting was to bring together, in one of the most important centers of northern Italy, both the expert and non-expert users of the AMP system and educate the attendees on how the ADVANCE® Medial Pivot family of products can be used in even the most complex cases.

The meeting was divided in two parts. One didactic, consisting of surgeons' presenting on their experience, they shared their own knowledge and provided a lot of tips and tricks. The second one was an interactive live surgery session.

More than 40 delegates coming from the north of Italy joined and the interaction level was very high during the entire meeting.






First SuperPath™ Hip Replacement Surgery in Zhejiang

On December 4, the first SuperPath™ hip replacement surgery in Zhejiang Province was successfully completed in Zhejiang Provincial People's Hospital. After the surgery, the surgeon spoke highly of our SuperPath™ tissue-sparing surgical techniques. This is another step forward for SuperPath™ to push into the China market and we believe this revolutionary surgical technique will gain higher recognition among patients and surgeons.



The 4th MicroPort Orthopedics Joint Arthroplasty Training

From December 7 to December 9, Shanghai MicroPort Orthopedics Co (“MicroPort Orthopedics Shanghai”) held the fourth Joint Arthroplasty Training in Shanghai Ninth People’s Hospital. Dr. Zhen’an Zhu and Dr. You Wang from Shanghai Ninth People’s Hospital were invited as tutors for the training. A total of 7 joint surgeons attended the training. Dr. Zhu and Dr. Wang gave presentations on total hip arthroplasty and total knee arthroplasty respectively. They also arranged surgery demonstrations with PROFEMUR® Z stem and ADVANCE® Medial Pivot Knee system to enable attendees to have better understandings in the products.



MicroPort Completes the First Bilateral SuperPath™ THA in China

MicroPort recently completed its first bilateral SuperPath™ Micro-posterior Total Hip Arthroplasty ("THA") in China.

The surgery, carried out by Professor Yanguo Qin in the Second Hospital of Jilin University, was a success. The patient, who suffered from bilateral femoral head necrosis, was back on his feet on the second day of the surgery and has started rehabilitative training.

According to Professor Qin, this surgery proved SuperPath™ surgical technique's advantage in preventing the risk of dislocation in posterior approach of hip replacement. Professor Qin said, at the end of the surgery, he tested dislocation in each angle and found out the patient's posterolateral hip was in stable condition.

SuperPath™ is a revolutionary surgical technique, as it is designed to precisely reconstruct the hip without cutting critical tendons and stretching or traumatizing muscles that are important to hip function. With SuperPath™, there is no surgical dislocation of the hip and the integrity of the capsule is completely preserved. Because of the elimination of damage to the important structures during reconstruction, patients typically have a short hospital stay.

With an aging population, there will be a growing demand for joint replacement surgeries in China and we believe SuperPath™ surgical techniques will benefit more Chinese patients in the future.



Medical Education: TKA/THA Saloon

On December 20, MicroPort Orthopedics Shanghai held a medical education featuring total knee arthroplasty (“TKA”) and total hip arthroplasty (“THA”) in Guangzhou, Guangdong Province. We invited four renowned surgeons to share their experiences with TKA and THA. A total of 35 people attended this saloon.

Dr. You Wang from Shanghai Ninth People’s Hospital, Dr. Baolin Li of Guangzhou Orthopedic Hospital and Dr. Weihong Zhang with Shenzhen Pingle Orthopedic Hospital, gave presentations on ADVANCE® Medial Pivot Knee System, SuperPath™ and Modular Stems respectively. They shared their surgical techniques and provided a lot of tips and tricks on how to deal with difficult cases.

Investor Newsletter

Issue **12** 2014



For more information, please contact:

Hongbin Sun

Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com

Xun You

Board Secretary
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com